Conference Material
|
Slide Presentation
Preliminary data on safety and effectiveness of six-month all-oral regimens in patients with rifampicin-resistant tuberculosis in Belarus
Yatskevich N,
Hurevich H,
Solodovnikova V,
Garsevanidze E,
Lachenal N,
Alvarez JL,
Sitali N,
Sinha A,
Skrahina A
View HTML
View PDF
Share
Download
Download
View PDF
Share
No abstract available
Countries
Belarus
Subject Area
antibiotic resistance
tuberculosis
antimicrobial resistance
Languages
English
DOI
10.57740/3sk2-bf43
Published Date
07 Jun 2023
Conference
MSF Scientific Day International 2023
Linked Content
Conference Material
|
Abstract
Preliminary data on safety and effectiveness of six-month all-oral regimens in patients with rifampicin-resistant tuberculosis in Belarus
2023 June 07 • MSF Scientific Day International 2023
Conference Material
|
Video
Preliminary data on safety and effectiveness of six-month all-oral regimens in patients with rifampicin-resistant tuberculosis in Belarus
2023 June 07 • MSF Scientific Day International 2023
Similar Content
Abstract
|
Abstract
Preliminary data on safety and effectiveness of six-month all-oral regimens in patients with rifampicin-resistant tuberculosis in Belarus
2023 June 07 • MSF Scientific Day International 2023
Video
|
Video
Preliminary data on safety and effectiveness of six-month all-oral regimens in patients with rifampicin-resistant tuberculosis in Belarus
2023 June 07 • MSF Scientific Day International 2023
Loading...